SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting
NCT ID: NCT02701439
Last Updated: 2016-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1050 participants
OBSERVATIONAL
2012-09-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of PCR Using DNA Extract From Slides and Filter Paper for the Detection of Tuberculosis and MDR-tuberculosis
NCT03137875
Acceptability and Feasibility of Home-based TB Testing
NCT04973371
Sputum-free Diagnostis of TB
NCT07125274
Probe Melting Technology for Rapid Detection of Drug Resistant Tuberculosis
NCT02776150
Improving the Diagnostic of Tuberculosis
NCT02861768
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The new test for TB diagnosis we are studying is called the Small Membrane Filtration (SMF) method. This test that is being compared to the method currently being used and is very similar to the one that is currently used (standard smear microscopy) but has the advantage of concentrating the sputum (mucus) so that we can more easily see if bacteria are present in the sputum. It is hoped that a better way of knowing if someone has TB will help doctors decide when people need to be treated for TB and when not, which will improve the health of patients and help avoid passing the infection to others.
This study will enroll 740 HIV-infected and 310 HIV-uninfected adults with culture confirmed pulmonary TB. These individuals will be identified prospectively at two TB clinics in Mbarara, Uganda.
Study hypothesis: The investigators will assume that one sputum sample will be equivalent to two (null hypothesis) with respect to sensitivity unless we have evidence that the use of two has higher sensitivity (alternative hypothesis). The investigators will assume that SMF is equivalent to AFB smear with respect to sensitivity and specificity unless the investigators find evidence it is superior. The investigators will assume that SMF is equivalent to Xpert unless the investigators find evidence that Xpert is superior.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIV-infected
Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB.
Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention
Small membrane filtration
Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention will be administered to both arms
HIV negative
Enrollment of 350 HIV negative adults with suspicion of pulmonary TB.
Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention
Small membrane filtration
Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention will be administered to both arms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Small membrane filtration
Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention will be administered to both arms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pulmonary TB suspect defined as any person who presents with a productive cough for more than 2 weeks AND accompanied by at least one other respiratory symptom (shortness of breath, chest pains, hemoptysis) and/or constitutional symptom (loss of appetite, weight loss, fever, night sweats, and fatigue) (6).
* Willing to undergo TB evaluation and spontaneously expectorate ≥2 mL of sputum
* Willing to be tested for HIV, if no results available within past 6 months
Exclusion Criteria
* Treated with TB drugs for more than 3 days
* Extra-pulmonary or disseminated TB without pulmonary involvement (i.e. no cough)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston University
OTHER
University of Florida
OTHER
Epicentre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yap Boum II, PhD
Role: PRINCIPAL_INVESTIGATOR
Epicentre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Epicentre Mbarara Research Base
Mbarara, Mbarara, Uganda
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMF-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.